Alpine Immune Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Alpine Immune Sciences's estimated annual revenue is currently $6.8M per year.
- Alpine Immune Sciences received $48.0M in venture funding in June 2016.
- Alpine Immune Sciences's estimated revenue per employee is $53,701
- Alpine Immune Sciences's total funding is $225.3M.
Employee Data
- Alpine Immune Sciences has 127 Employees.
- Alpine Immune Sciences grew their employee count by 0% last year.
Alpine Immune Sciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Regulatory Affairs | Reveal Email/Phone |
2 | VP, Translational Medicine | Reveal Email/Phone |
3 | Executive Director, Human Resources | Reveal Email/Phone |
4 | Director, Preclinical Pharmacology | Reveal Email/Phone |
5 | SVP, Chief Financial Officer | Reveal Email/Phone |
6 | Director Finance | Reveal Email/Phone |
7 | Director Information Technology | Reveal Email/Phone |
8 | Executive Director, Translational Medicine | Reveal Email/Phone |
9 | Sr. Director Supply Operations | Reveal Email/Phone |
10 | Associate Director, Clinical Contracts and Payments | Reveal Email/Phone |
Alpine Immune Sciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $5.7M | 37 | 42% | N/A | N/A |
#5 | $1.4M | 18 | -10% | N/A | N/A |
#6 | $3.7M | 48 | -21% | $16M | N/A |
#7 | $1.1M | 7 | 0% | N/A | N/A |
#8 | $0.8M | 5 | -81% | N/A | N/A |
#9 | $2.5M | 16 | -27% | N/A | N/A |
#10 | $0.8M | 5 | -17% | N/A | N/A |
What Is Alpine Immune Sciences?
Founded in 2015 by a team responsible for the FDA's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. Traded on NASDAQ under ticker ALPN.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$225.3M
Total Funding
127
Number of Employees
$6.8M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Alpine Immune Sciences News
Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Expected to Post Earnings of -$0.17 Per Share. Posted by admin on Apr 13th, 2022.
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint...
Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event. - AACR Investor Event time change to 6:30 p.m. ET - -...
We can see that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) does use debt in its business. But should shareholders be worried about its ...
Other Companies in Seattle
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $41M | 127 | -4% | N/A |
#2 | $34.3M | 127 | 2% | N/A |
#3 | $36.8M | 127 | 5% | N/A |
#4 | $26.1M | 128 | -2% | $18.8M |
#5 | $32.1M | 128 | 5% | $135.6M |
Alpine Immune Sciences Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2016-06-14 | $48.0M | A | OrbiMed Advisors | Article |